Cyclerion appoints Steven E. Hyman to board; former NIMH director and neuroscience leader

Cyclerion Therapeutics, Inc.

Steven Hyman appointed to Board effective July 25, 2022, following Board expansion from 8 to 9 members.
Hyman serves on Science Committee; is director of Stanley Center for Psychiatric Research at Broad Institute.
Previously served as director of NIMH (1996-2001) and provost of Harvard University (2001-2011).
Will help shape clinical strategy for lead molecule CY6463 and expand external collaborations.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Steven E. Hyman, M.D.

director

CYCN · Cyclerion Therapeutics, Inc.

Effective: 2022-07-25
Filed: July 26, 2022, 7:59 PM ET

Cyclerion Therapeutics, Inc. (the “Company”) has announced that Steven E. Hyman, M.D., was appointed to the Company’s board of directors (the “Board”) on July 25, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Steven E. Hyman, M.D. was appointed as director at Cyclerion Therapeutics, Inc..

Action: appointed
Role: director

Exact text from the filing

Cyclerion Therapeutics, Inc. (the “Company”) has announced that Steven E. Hyman, M.D., was appointed to the Company’s board of directors (the “Board”) on July 25, 2022.

View on SEC.gov

Cyclerion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-22-026908

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.